# A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

> **NCT06499688** · PHASE3 · COMPLETED · sponsor: **Chongqing Claruvis Pharmaceutical Co., Ltd.** · enrollment: 529 (actual)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** Rcombinant botulinum neurotoxin type A for injection (YY001)
- **BIOLOGICAL:** OnabotulinumtoxinA
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06499688
- **Lead sponsor:** Chongqing Claruvis Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-28
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-05-31
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06499688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06499688, "A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06499688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*